148 related articles for article (PubMed ID: 19904011)
21. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
Mousa SA
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828
[TBL] [Abstract][Full Text] [Related]
22. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
Hamilton SF; Miller MW; Thompson CA; Dale GL
J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
[TBL] [Abstract][Full Text] [Related]
23. Von Willebrand factor can support platelet aggregation via interaction with activated GPIIb-IIIa and GPIb.
Naimushin YA; Mazurov AV
Platelets; 2004 Nov; 15(7):419-25. PubMed ID: 15745313
[TBL] [Abstract][Full Text] [Related]
24. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Mousa SA; Bozarth JM; Forsythe MS; Slee A
Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
[TBL] [Abstract][Full Text] [Related]
25. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
26. FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2.
Huang TF; Chang CH; Ho PL; Chung CH
Exp Hematol; 2008 Dec; 36(12):1704-13. PubMed ID: 18809237
[TBL] [Abstract][Full Text] [Related]
27. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
28. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
30. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
[TBL] [Abstract][Full Text] [Related]
31. Reassociation and translocation of glycoprotein IIB-IIIA in EDTA-treated human platelets.
Ma Y; Wong K
Platelets; 2007 Sep; 18(6):451-9. PubMed ID: 17763154
[TBL] [Abstract][Full Text] [Related]
32. Recombinant P-selectin glycoprotein-ligand-1 delays thrombin-induced platelet aggregation: a new role for P-selectin in early aggregation.
Théorêt JF; Chahrour W; Yacoub D; Merhi Y
Br J Pharmacol; 2006 Jun; 148(3):299-305. PubMed ID: 16633357
[TBL] [Abstract][Full Text] [Related]
33. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
[TBL] [Abstract][Full Text] [Related]
34. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
Mousa SA; Forsythe M; Bozarth J; Jin F; Confalone PN
Coron Artery Dis; 2000 Oct; 11(7):563-70. PubMed ID: 11023245
[TBL] [Abstract][Full Text] [Related]
35. Differential efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet/fibrin-mediated clot dynamics under different conditions using thrombelastography: the critical need for anticoagulant.
Mousa SA; Forsythe MS; Bozarth JM
Coron Artery Dis; 2002 Jun; 13(4):243-8. PubMed ID: 12193852
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
[TBL] [Abstract][Full Text] [Related]
37. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
[TBL] [Abstract][Full Text] [Related]
38. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Furman MI; Krueger LA; Frelinger AL; Barnard MR; Mascelli MA; Nakada MT; Michelson AD
Thromb Haemost; 2000 Sep; 84(3):492-8. PubMed ID: 11019977
[TBL] [Abstract][Full Text] [Related]
39. Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: observed differences in GPIIb-IIIa functional activity.
Jennings LK; White MM; Mandrell TD
Thromb Haemost; 1995 Dec; 74(6):1551-6. PubMed ID: 8772236
[TBL] [Abstract][Full Text] [Related]
40. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
Pedicord DL; Thomas BE; Mousa SA; Dicker IB
Thromb Res; 1998 Jun; 90(6):247-58. PubMed ID: 9700855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]